Evidence map›Paper›PMID 27010548›Full record

ArticlePLoS pathogens2016

Genome-wide siRNA Screening at Biosafety Level 4 Reveals a Crucial Role for Fibrillarin in Henipavirus Infection.

Celine Deffrasnes, Glenn A Marsh, Chwan Hong Foo, Christina L Rootes, Cathryn M Gould, Julian Grusovin, Paul Monaghan, Michael K Lo, S Mark Tompkins, Timothy E Adams and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Advances in the structure and function of the nucleolar protein fibrillarin.Frontiers in cell and developmental biology · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Celine DeffrasnesCSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia.
Glenn A MarshCSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia.
Chwan Hong FooCSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia.
Christina L RootesCSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia.
Cathryn M GouldVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Julian GrusovinCSIRO Manufacturing, Parkville, Victoria, Australia.
Paul MonaghanCSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia.
Michael K LoCenters for Disease Control & Prevention, Viral Special Pathogens Branch, Atlanta, Georgia, United States of America.
S Mark TompkinsDepartment of Infectious Diseases, University of Georgia, Athens, Georgia, United States of America, and School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia.
Timothy E AdamsCSIRO Manufacturing, Parkville, Victoria, Australia.
John W LowenthalCSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia.
Kaylene J SimpsonVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Cameron R StewartCSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia.
Andrew G D BeanCSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia.
Lin-Fa WangCSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia.
Australian Centre for Disease Preparedness · AUCSIRO Health and Biosecurity · AUCSIRO Manufacturing · AUDeakin University · AUCenters for Disease Control and Prevention · USPeter MacCallum Cancer Centre · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hendra and Nipah viruses (genus Henipavirus, family Paramyxoviridae) are highly pathogenic bat-borne viruses. The need for high biocontainment when studying henipaviruses has hindered the development of therapeutics and knowledge of the viral infection cycle. We have performed a genome-wide siRNA screen at biosafety level 4 that identified 585 human proteins required for henipavirus infection. The host protein with the largest impact was fibrillarin, a nucleolar methyltransferase that was also required by measles, mumps and respiratory syncytial viruses for infection. While not required for cell entry, henipavirus RNA and protein syntheses were greatly impaired in cells lacking fibrillarin, indicating a crucial role in the RNA replication phase of infection. During infection, the Hendra virus matrix protein co-localized with fibrillarin in cell nucleoli, and co-associated as a complex in pulldown studies, while its nuclear import was unaffected in fibrillarin-depleted cells. Mutagenesis studies showed that the methyltransferase activity of fibrillarin was required for henipavirus infection, suggesting that this enzyme could be targeted therapeutically to combat henipavirus infections.

Indexed as

AnimalsChlorocebus aethiopsChromosomal Proteins, Non-HistoneHeLa CellsHendra VirusHenipavirus InfectionsHumansMutationNipah VirusRNA, Small InterferingVero CellsViral Matrix ProteinsChromosomal Proteins, Non-HistonefibrillarinRNA, Small InterferingViral Matrix Proteins

Identifiers

PMID27010548
PMCPMC4806981
OpenAlexW2304684998

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.